Participants in each cohort will be randomized to receive treatment with TAK-071 or matching placebo using drug-in-capsule (DIC) in the morning following a minimum fast of 8 hours. In Cohort 16, participants will be assigned to 1 of 2 possible treatments, TAK-071 or matching placebo. In Cohort 17, 12 participants will be assigned to 1 of 3 treatment sequences (ABC, BCA, or CAB) with treatment A being Fasted State and Capsule Formulation, Treatment B being Fasted State and Tablet Formulation, and Treatment being C Fed State and Tablet Formulation (10 mg tablet formulation). In Cohorts 20-22, participants will be administered as a single dose of TAK-071 or placebo on Day 1, and a single dose of donepezil or placebo approximately 24 hours later on Day 2.